Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 5/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.54 |
| ▸ | ALPL | P05186 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CFD | P00746 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16235908 | 0.86 | HRH4 (0.56) | XDHHRH4ALPLCYP1A2 | |
| SCHEMBL21235447 | 0.83 | XDH (0.55) | XDHHRH4ALPLCYP1A2GLA | |
| SCHEMBL2770162 | 0.83 | KDM4E (0.51) | XDHHRH4GLAGAAKDM4E | |
| SCHEMBL24113538 | 0.80 | HRH4 (0.54) | HRH4 | |
| SCHEMBL2576853 | 0.79 | HPGD (0.56) | HRH4KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL24843559 | 0.78 | XDH (0.56) | XDHALPLCYP1A2GLAGAA | |
| SCHEMBL4787473 | 0.77 | HRH4 (0.54) | HRH4KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL25764958 | 0.77 | HRH4 (0.54) | HRH4KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL21685727 | 0.76 | XDH (0.45) | XDHHRH4ALPLCYP1A2GLA | |
| SCHEMBL4276853 | 0.75 | ULK1 (0.49) | XDHALPLCYP1A2GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189838-B2 | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMAN-LA ROCHE INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180072726-A9 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2018-03-15 | — | — | US | disclosed |
| EP-2997028-A1 | AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | F.HOFFMANN-LA ROCHE AG (CH) | 2016-03-23 | — | — | EP | disclosed |
| US-20160068531-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2016-03-10 | — | — | US | disclosed |
| WO-2014184163-A1 | AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2014-11-20 | — | — | WO | disclosed |
| EP-1451185-B1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2014-08-06 | — | — | EP | disclosed |
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
| US-6906084-B2 | Indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-14 | — | — | US | disclosed |
| US-20050043302-A1 | New indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-02-24 | — | — | US | disclosed |
| EP-1451185-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2004-09-01 | — | — | EP | disclosed |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-10-23 | — | — | US | disclosed |
| WO-2003044014-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | F12, F5, F2 | XDH 84/4885HRH4 471/4885ALPL 2473/4885 |
| US-20160068531-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | ZC3HAV1, IDO1, AZI2 | XDH 172/4885HRH4 417/4885ALPL 3237/4885 |
| US-20180072726-A9 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | ZC3HAV1, IDO1, AZI2 | XDH 172/4885HRH4 417/4885ALPL 3237/4885 |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | F5, F12, F2 | XDH 64/4885HRH4 848/4885ALPL 2187/4885 |
| US-10189838-B2 | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection | IDO1, ZC3HAV1, AZI2 | XDH 161/4885HRH4 371/4885ALPL 3095/4885 |
| US-20050043302-A1 | New indole derivatives as factor Xa inhibitors | F12, F5, F2 | XDH 129/4885HRH4 626/4885ALPL 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.